Boston Commerce

Which are the latest news on Boston Commerce?

Why is Boston Commerce Limited falling/rising?

As of 05-Sep, Boston Commerce Limited's stock price is stable at 5.20, but it has declined significantly over the long term, with a year-to-date drop of 28.47%. Despite recent short-term gains, indicators suggest challenges ahead due to reduced investor participation and long-term weakness.

As of 05-Sep, Boston Commerce Limited's stock price is currently stable at 5.20, showing no change from the previous trading session. However, the stock has experienced a significant decline over the longer term, with a year-to-date decrease of 28.47% and a one-year decline of 38.68%. <BR><BR>In the short term, the stock has shown some positive momentum, outperforming the sector by 3.54% today, despite the broader Medical Equipment/Supplies/Accessories sector falling by 3.75%. Additionally, the stock's performance over the past week has been strong, with a gain of 13.29%, while the Sensex has decreased by 0.97%. <BR><BR>Despite these recent gains, there are concerning indicators. The stock's delivery volume has dropped significantly, with a reported decline of 85.07% against the 5-day average, suggesting falling investor participation. Furthermore, while the stock is currently above its 5-day, 20-day, and 50-day moving averages, it remains below its 100-day and 200-day moving averages, indicating potential weakness in the longer-term trend.<BR><BR>Overall, while there are some short-term positive movements, the long-term decline and reduced investor participation suggest that Boston Commerce Limited's stock is facing challenges that could hinder its recovery.

Who are in the management team of Boston Commerce?

The management team of Boston Commerce includes Ramesh Kumar G Dave (Managing Director), Sanjay Sodani, Kushal Rathore, Amit Ashwinbhai Pandya, Ankit Sanjay Disoja, Narendra Mathurbhai Gandhi (all Non Executive Directors), and Seema Baghel (Additional Independent Director).

The management team of Boston Commerce includes the following individuals:<BR><BR>1. Ramesh Kumar G Dave - Managing Director<BR>2. Sanjay Sodani - Non Executive Director<BR>3. Kushal Rathore - Non Executive Independent Director<BR>4. Amit Ashwinbhai Pandya - Non Executive Director<BR>5. Ankit Sanjay Disoja - Non Executive Director<BR>6. Narendra Mathurbhai Gandhi - Non Executive Director<BR>7. Seema Baghel - Additional Director (Independent)<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

What does Boston Commerce do?

Boston Commerce Limited trades medical equipment and testing kits in the healthcare sector, having transitioned from its original focus on share broking. As of March 2026, it has a market cap of INR 3 Cr and reported a net profit of -1 Cr.

Overview: <BR>Boston Commerce Limited is engaged in the trading of medical equipment and testing kits within the healthcare services industry and falls under the micro-cap market category.<BR><BR>History: <BR>Boston Commerce Limited was incorporated on April 17, 1995. Initially, the company was involved in share broking, investment, and trading in shares and derivatives. Currently, it focuses on trading goods such as medical equipment and testing instruments. The latest quarterly results reported are for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 3 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>Industry P/E: 112 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price to Book: 0.00<BR><BR>Contact Details: <BR>Address: 17/B 4th Floor Mirzapur, Sandesh Commercial Complex Ahmedabad Gujarat : 380001 <BR>Tel: 91-9098433517 <BR>Email: bostonsystem@yahoo.com <BR>Website: http://www.bostonbiosystemltd.com

Who are the peers of the Boston Commerce?

Peers of Boston Commerce include Samsrita Labs, Transgene Biotek, Vanta Bioscience, Family Care, and others. Family Care shows excellent management and growth, while Dhanvantri Jeev. has the highest 1-year return at 26.19%, and Gian Lifecare has the lowest at -67.47%.

Peers: The peers of Boston Commerce are Samsrita Labs, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Family Care, Looks Health, Clinitech Lab, Dr Lalchand. Lab, Ashram Online, Gian Lifecare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Average management risk is found at Family Care, and Below Average management risk is noted at Vanta Bioscience, Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, and the rest. Growth is rated as Good at Family Care, while Below Average growth is seen at Vanta Bioscience, Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, and the rest. Capital Structure is rated as Excellent at Family Care, Good at Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, and the rest, while the rest do not qualify.<BR><BR>Return Snapshot: Dhanvantri Jeev. has the highest 1-year return at 26.19%, while Gian Lifecare has the lowest at -67.47%, with Boston Commerce's own 1-year return at -45.95% being higher than Gian Lifecare's. Additionally, several peers, including Samsrita Labs, Transgene Biotek, Vanta Bioscience, Family Care, Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, have negative six-month returns.

How big is Boston Commerce?

As of 31st August, Boston Commerce Limited has a market capitalization of 3.00 Cr, with Net Sales of 0.48 Cr and a Net Profit loss of 0.58 Cr over the latest four quarters. Shareholder's Funds are 5.90 Cr and Total Assets are 14.90 Cr as of March 2025.

As of 31st August, Boston Commerce Limited has a market capitalization of 3.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Boston Commerce reported Net Sales of 0.48 Cr. However, the company experienced a loss of 0.58 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 5.90 Cr and Total Assets were reported at 14.90 Cr.

When is the next results date for Boston Commerce Limited?

The next results date for Boston Commerce Limited is 14 August 2026.

The next results date for Boston Commerce Limited is scheduled for 14 August 2026.

How has been the historical performance of Boston Bio?

Boston Bio has experienced significant financial decline, with net sales dropping from 1.50 Cr in March 2016 to 0.19 Cr in March 2025, alongside increasing losses and negative cash flow. The company reported an operating profit of -0.55 Cr in March 2025, reflecting ongoing operational challenges.

Answer:<BR>The historical performance of Boston Bio shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Boston Bio's net sales have seen a notable decline from 1.50 Cr in March 2016 to just 0.19 Cr in March 2025, with a complete absence of sales in the intervening years of March 2017, March 2018, and March 2024. The total operating income followed a similar trend, peaking at 1.50 Cr in March 2016 and dropping to 0.19 Cr in March 2025. The company has consistently reported no raw material costs or purchase of finished goods, indicating a lack of production activity. Total expenditure, however, increased to 0.74 Cr in March 2025, up from 0.14 Cr in March 2024, primarily driven by other expenses. This led to an operating profit (PBDIT) of -0.55 Cr in March 2025, reflecting a negative operating profit margin of -289.47%. The profit before tax and profit after tax also mirrored this negative trend, both standing at -0.55 Cr in March 2025. The earnings per share (EPS) further illustrate the company's struggles, with an EPS of -0.79 in March 2025 compared to -0.20 in March 2024. Cash flow from operating activities was -4.00 Cr in March 2025, indicating a significant cash outflow, while cash flow from financing activities was positive at 4.00 Cr, suggesting reliance on external financing to manage operations. Overall, Boston Bio's financial performance has been characterized by declining sales, increasing losses, and negative cash flow, highlighting ongoing challenges in its business operations.

Who are the top shareholders of the Boston Bio?

The top shareholders of Boston Bio are Jyotshna Jagdishchandra Shah with 2.14% and Mayank Doshi with 2.6%. Individual investors hold a significant 85.33% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Boston Bio include Jyotshna Jagdishchandra Shah, who holds the highest promoter stake at 2.14%. The highest public shareholder is Mayank Doshi, with a holding of 2.6%. Additionally, individual investors collectively own a significant portion of the company, accounting for 85.33% of the shares. There are no institutional holdings or pledged promoter holdings reported.

What is the technical trend for Boston Bio?

As of June 5, 2025, Boston Bio's trend has shifted to bearish, supported by weekly MACD and Bollinger Bands, while daily moving averages confirm this trend, despite mixed signals from the KST and unclear indications from RSI and Dow Theory.

As of 5 June 2025, the technical trend for Boston Bio has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly MACD and Bollinger Bands, both signaling bearish conditions. The daily moving averages also confirm a bearish trend. The KST shows a mixed signal with a bearish weekly reading and a bullish monthly reading, indicating some divergence in longer-term momentum. Overall, the lack of clear signals from the RSI and Dow Theory suggests a continuation of the bearish trend without any immediate reversal in sight.

Has Boston Bio declared dividend?

No Dividend History Available